Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Beacon Therapeutics logo — Transforming Vision, Transforming Lives

Beacon Therapeutics

Transforming Vision, Transforming Lives

Founded 2023 United Kingdom London, United Kingdom 95 employees Series C Total: $341.00M Biotechnology, Health Care +1

General Information

Company Name Beacon Therapeutics
Founded Year 2023
Location United Kingdom London, United Kingdom
Employees 95
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with Beacon Therapeutics. To contact Beacon Therapeutics, visit beacontx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Beacon Therapeutics compare?

A PDF of Beacon Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Beacon Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Beacon Therapeutics

Beacon Therapeutics is a United States based ophthalmic gene therapy company that aims to restore and enhance the sight of patients suffering from a variety of prevalent and rare retinal diseases leading to blindness. The company's scientific foundation encompasses a late-stage development candidate for treating X-linked retinitis pigmentosa (XLRP), along with two preclinical programs targeting dry age-related macular degeneration (AMD) and cone-rod dystrophy (CRD), an inherited retinal disease from the University of Oxford. The lead development candidate, AGTC-501, is a gene therapy program currently in Phase II clinical trials to treat XLRP, a disorder causing progressive vision loss primarily in boys and young men. The company's access to a target generation technology platform for identifying, screening, and researching secreted proteins in the ophthalmology space bolsters its offerings. Beacon Therapeutics is financially backed by funds from Syncona and other investors, including Oxford Science Enterprises. The company secured a £96.00M Series A investment on 12 June 2023. For more information, visit their website at www.beacontx.com.

Business keywords: ophthalmic gene therapy, retinal diseases, X-linked retinitis pigmentosa, AMD (age-related macular degeneration), Cone-rod dystrophy, gene therapy program, RPGR gene, clinical trials, target generation technology, Syncona, Oxford Science Enterprises, inherited retinal diseases, vision restoration, blindness

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $75.00M 6
Advent Life Sciences Goldman Sachs Forbion
Advent Life Sciences, Goldman Sachs +4
01 Jan 2026
Series B $170.00M 5
Advent Life Sciences Forbion Oxford Science Enterprises
Advent Life Sciences, Forbion +3
01 Jul 2024
Series A £96.00M 2
Oxford Science Enterprises Syncona Investment Management
Oxford Science Enterprises, Syncona Investment Management
01 Jun 2023
Spinout Undisclosed 1
The University of Oxford
The University of Oxford
01 Jan 2023

Beacon Therapeutics Alternatives & Competitors

View All Alternatives
Beacon Therapeutics vs
Ray Therapeutics, Inc.
Ray Therapeutics, Inc. United States

Optogenetic Gene Therapy Company

Series B
46 employees
Biotechnology, Health Care
Compare Beacon Therapeutics vs Ray Therapeutics, Inc.
Beacon Therapeutics vs
LambdaVision, Inc.
LambdaVision, Inc. United States

Leveraging Space to Restore Vision with a Protein-Based Artificial Retina

Seed
14 employees
Biotechnology, Health Care
Compare Beacon Therapeutics vs LambdaVision, Inc.
Beacon Therapeutics vs
CiRC Biosciences
CiRC Biosciences United States

A privately held, cell therapy company, developing treatments for serious diseases, with an initial...

Debt Financing
12 employees
Biotechnology, Health and Wellness
Also compare with: Beacon Therapeutics vs GenSight Biologics GenSight Biologics View all alternatives

FAQ About Beacon Therapeutics

Transforming Vision, Transforming Lives
Beacon Therapeutics was founded in 2023.
Beacon Therapeutics is headquartered in London, United Kingdom.
Beacon Therapeutics operates in Biotechnology, Health Care and Health and Wellness. Its work centres on ophthalmic gene therapy, retinal diseases, X-linked retinitis pigmentosa and AMD (age-related macular degeneration).
Beacon Therapeutics has approximately 95 employees.
Beacon Therapeutics has completed 4 funding rounds, raising a total of $341.00M. The latest funding stage is Series C.
Top alternatives and competitors to Beacon Therapeutics include Ray Therapeutics, Inc., LambdaVision, Inc., CiRC Biosciences, RetroSense Therapeutics, GenSight Biologics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Beacon Therapeutics and Ray Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Beacon Therapeutics, https://bouncewatch.com/company/beacon-therapeutics, updated 28 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout